Skip to main content
Clinical Trials/ISRCTN36646813
ISRCTN36646813
Completed
未知

Early treatment of idiopathic Parkinson's disease with dopaminergic agonist piribedil in monotherapy. A two-year randomised, parallel, placebo-controlled study in idiopathic Parkinsonian de novo patients

Institut de Recherches Internationales Servier (France)0 sites400 target enrollmentMarch 31, 2006

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Institut de Recherches Internationales Servier (France)
Enrollment
400
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 31, 2006
End Date
August 11, 2004
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Institut de Recherches Internationales Servier (France)

Eligibility Criteria

Inclusion Criteria

  • Out\-patients between 30 to 77 years old, with stage 1 to 3 (Hoehn and Yahr) and less than six weeks of previous L\-dopa treatment, with less than 3 months of previous treatment by a dopaminergic agonist

Exclusion Criteria

  • 1\. Patients frequently falling according to unified Parkinson's disease rating scale (UPDRS) II and/or III
  • 2\. Prior experience of a dopaminergic complication
  • 3\. Prior neurosurgery for PD
  • 4\. Previous history of freezing
  • 5\. Suspected autosomal juvenile Parkinsonism
  • 6\. Atypical Parkinsonian symtoms caused by drugs, metabolic disorders or encephalitis
  • 7\. History of psychotic symptoms
  • 8\. Poor cognitive performance

Outcomes

Primary Outcomes

Not specified

Similar Trials